Clinical trials: Neoadjuvant Chemoradiotherapy
Nasopharyngeal Carcinoma
A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
This study is a multicenter trial.The primary objective is to estimate short-term efficacy and acute toxicities of nedaplatin to the combination of docetaxel in neoadjuvant chemotherapy followed by nedaplatin in concurrent…
- Trial name
- NCT01479504
- Testing
- nedaplatin and docetaxel, cisplatin and docetaxel
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Guangxi Medical University
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer
This is a prospective, single-arm phase II clinical trial intended to investigate the efficacy of neoadjuvant CTLA-4 monoclonal antibody combined with PD-1 monoclonal antibody plus preoperative chemoradiotherapy for locally…
- Trial name
- NEOCRTE2601 (NCT07751055)
- Testing
- Ipilimumab (1mg/kg), Sinitilimab, Nab-paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer
Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics
This study plans to construct a MR radiomics model for predicting pathological complete response(pCR) to neoadjuvant chemoradiotherapy(CRT) in locally advanced rectal cancer(LARC) patients.
- Trial name
- NCT03238885
- Testing
- pelvic MR examination
- Where
- China
- Volunteers
- 538 people
- Sponsor
- Sun Ying-Shi
Rectal Neoplasms
Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial
This study evaluates whether an arginine-free diet combined with chemoradiotherapy can improve treatment outcomes in patients with locally advanced rectal cancer.
- Trial name
- NCT07755124
- Testing
- Arginine-Deprived Diet, Short-Course Radiotherapy (SCRT), CAPOX + PD-1 Inhibitor
- Volunteers
- 140 people
- Sponsor
- West China Hospital
Gastroesophageal Junction Adenocarcinoma
Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study
The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 Positive adenocarcinoma at gastroesophageal junction
- Trial name
- NCT03368131
- Testing
- Trastuzumab, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hebei Medical University
Neoplasm, Rectum
Appropriate Timing of Surgery After Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
This study aimed to compare the outcomes of early versus late surgical resection in patients who underwent curative total mesorectal excision after neoadjuvant chemoradiation.
- Trial name
- NCT03287843
- Testing
- Total mesorectal excision before 56 days (4-8 weeks), Total mesorectal excision after 56 days (8-12 weeks)
- Volunteers
- 350 people
- Sponsor
- Ege University
Esophageal Cancer
Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00425425
- Testing
- cetuximab, fluorouracil, oxaliplatin
- Where
- 3 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Technical University of Munich
Rectal Neoplasms
MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer
Improvements in downstaging are required when using preoperative chemoradiation for unresectable rectal cancer. There is therefore a need to explore more effective schedules.
- Trial name
- SUNRISE (NCT03714490)
- Testing
- SCPRT, CRT, CAPOX
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small-Cell Lung Carcinoma, Surgery
N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation
The objective of this multicenter retrospective study is to compare overall survival in patients with stage IIIA-N2 NSCLC treated with neoadjuvant treatment and surgery versus definitive chemoradiation.
- Conditions
- Non-small-Cell Lung Carcinoma, Surgery, Stage IIIA-N2, Chemoradiation
- Trial name
- NCT02966769
- Testing
- Overall survival
- Where
- Spain
- Volunteers
- 294 people
- Sponsor
- Grupo de Investigación Clínica en Oncología Radioterapia
Non-small Cell Lung Cancer
Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer
This phase II trial is to compare neoadjuvant chemotherapy with concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer (NSCLC) to address optimal induction strategy.
- Trial name
- NCT01054482
- Testing
- Pre-operative chemotherapy, Pre-operative concurrent chemoradiation therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Rectal Neoplasms
Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer
Locally advanced rectal cancer (T3, T4 or lymph node positive tumors) are conventionally treated with 5FU / capecitabine based chemoradiation prior to surgical resection.
- Trial name
- NCT02137356
- Testing
- standard dose pelvic radiation therapy, standard dose capecitabine, dose-escalated selinexor treatment
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Sheba Medical Center
Rectal Cancer
Induction Chemotherapy for Locally Advanced Rectal Cancer
Despite developments in the multidisciplinary treatment of patients with locally advanced rectal cancer (LARC), such as the introduction of total mesorectal excision (TME) by Heald et al.
- Trial name
- MEND-IT (NCT04838496)
- Testing
- FOLFOXIRI Protocol
- Where
- 13 sites in Netherlands
- Volunteers
- 128 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Locally Advanced, High-Risk
Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer
This is a single arm, open-label, prospective clinical trial to evaluate the combination of neoadjuvant short-course radiotherapy and toripalimab (PD-1 antibody) for locally advanced rectal cancer (LARC) patients with high risk…
- Conditions
- Locally Advanced, High-Risk, Rectal Cancer, MSS
- Trial name
- NCT05877573
- Testing
- Toripalimab, short-term radiotherapy, Oxaliplatin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Nanfang Hospital, Southern Medical University